WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
No more cute snaps of Mt Fuji. A screen is up in a Japanese town to prevent tourist crowds
Ningshan County in NW China makes efforts in ecological protection and green development
Xi Sends Congratulations to 32nd Arab League Summit
Peng Liyuan, Spouses of Central Asian Leaders Visit Historic Theater
Wayne Bennett, at 74, signs a 3
Tourism provides development engine for village
Xi Jinping: Guarding Tropical Rainforest
In pics: Snow Town scenic spot in Hailin City, Heilongjiang
Vikings seek new deal with Justin Jefferson; star WR absent so far from workouts, AP source says
China, DRC Upgrade Ties to Comprehensive Strategic Cooperative Partnership